```html

Juxtacapillary (Membranous) Nephropathy

Overview

Juxtacapillary nephropathy, more commonly known as membranous nephropathy (MN), is a kidney disorder characterized by thickening of the glomerular basement membrane due to the deposition of immune complexes on the outer (subepithelial) side of the capillary wall. This immune‑mediated injury compromises the kidney’s ability to filter blood properly, frequently leading to a condition called nephrotic‑range proteinuria (excess protein loss in the urine).

Who it affects: MN can occur at any age but shows a bimodal distribution:

• Primary (idiopathic) MN: most common in adults aged 30–60 years, with a slight male predominance.
• Secondary MN: linked to other diseases (autoimmune, infections, drugs, malignancies) and can appear in younger or older patients.

Prevalence: In the United States, MN accounts for about 10–15% of adult nephrotic syndrome cases and an estimated 0.5–1 case per 100,000 people per year (Mayo Clinic, 2023). Worldwide incidence varies with ethnicity and exposure to known triggers (e.g., hepatitis B in Asia).

Symptoms

Because MN primarily causes protein loss, most patients present with classic nephrotic‑syndrome features, but the presentation can be subtle early on.

Typical nephrotic‑syndrome manifestations

• Proteinuria: ≥3.5 g/24 h of protein in the urine, often discovered on routine dipstick screening.
• Edema: Swelling (pitting edema) of the ankles, feet, legs, and sometimes the face or abdomen due to fluid retention.
• Hypoalbuminemia: Low blood albumin (<3.0 g/dL) caused by urinary loss, contributing to edema.
• Hyperlipidemia: Elevated cholesterol and triglycerides; the liver overproduces lipoproteins in response to low oncotic pressure.

Additional signs and symptoms

• Foamy or frothy urine: A visual clue to heavy protein loss.
• Weight gain: Rapid gain from fluid accumulation.
• Fatigue and malaise: Resulting from anemia, low albumin, or reduced kidney function.
• Reduced urine output (oliguria): May indicate worsening kidney function.
• Hematuria: Microscopic blood in urine is less common but can occur, especially in secondary MN.
• Blood pressure elevation: Hypertension is present in up to 30% of patients and may worsen over time.
• Thrombotic events: Severe hypoalbuminemia (<2 g/dL) predisposes to blood clots, especially in the renal vein or deep veins of the legs.

Causes and Risk Factors

MN is divided into two broad categories based on etiology.

Primary (idiopathic) MN

• Autoantibodies to phospholipase A₂ receptor (PLA₂R): Detected in ~70–80% of primary cases. These antibodies form immune complexes that settle under the glomerular podocytes.
• Thrombospondin type‑1 domain‑containing 7A (THSD7A) antibodies: Present in ~2–5% of primary MN.
• Genetic predisposition: HLA‑DQ2 and HLA‑DQ6 alleles increase susceptibility.

Secondary MN

• Autoimmune diseases: Systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s syndrome.
• Infections: Hepatitis B, hepatitis C, HIV, syphilis, and malaria.
• Cancers: Solid tumors (lung, colon, breast, melanoma) and hematologic malignancies (lymphoma, leukemia). Paraneoplastic MN often resolves after tumor treatment.
• Medications & toxins: Non‑steroidal anti‑inflammatory drugs (NSAIDs), gold salts, penicillamine, and newer agents such as immune checkpoint inhibitors.
• Other systemic conditions: Diabetes mellitus (rarely), sarcoidosis, and amyloidosis.

Risk factors that increase the likelihood of developing or progressing MN

• Male sex (primary MN)
• Age 30–60 years (peak incidence)
• Family history of autoimmune kidney disease
• Exposure to known secondary triggers (e.g., chronic hepatitis B infection)
• High baseline proteinuria (>5 g/24 h) – predicts faster decline in kidney function

Diagnosis

The diagnostic pathway combines clinical assessment, laboratory testing, imaging, and definitive kidney biopsy.

Initial laboratory evaluation

• Urinalysis: Detects proteinuria (quantified by urine protein‑to‑creatinine ratio or 24‑hour collection) and possible microscopic hematuria.
• Serum albumin and total protein: Low values confirm hypoalbuminemia.
• Lipid profile: Hypercholesterolemia is common.
• Serum creatinine & eGFR: Baseline kidney function; MN often presents with preserved eGFR initially.
• Immunologic panel: PLA₂R and THSD7A antibody titers (ELISA or indirect immunofluorescence). Positive PLA₂R strongly suggests primary MN.
• Secondary work‑up: Hepatitis B/C serologies, HIV test, ANA, complement levels (C3, C4), serum protein electrophoresis, and age‑appropriate cancer screening (CT, colonoscopy, mammography) when indicated.

Imaging

• Renal ultrasound: Usually normal or shows mildly enlarged kidneys; helps rule out obstruction.
• Chest X‑ray or CT (if pulmonary involvement suspected): Part of systemic disease evaluation.

Kidney biopsy – the gold standard

Indications for biopsy include unexplained nephrotic‑range proteinuria, rapid decline in eGFR, or suspicion for secondary causes.

• Light microscopy: Diffuse thickening of the glomerular basement membrane without significant hypercellularity.
• Immunofluorescence: Granular deposits of IgG (predominantly IgG4 in primary MN) along the capillary loops.
• Electron microscopy: Subepithelial immune complex “spike and dome” appearance, pathognomonic for MN.

Staging and prognostic scoring

Several scoring systems utilize baseline proteinuria, eGFR, and PLA₂R antibody level to predict 5‑year outcomes. For example, the Kidney Disease: Improving Global Outcomes (KDIGO) risk calculator estimates a 30–50% chance of reaching end‑stage renal disease (ESRD) within 10 years for patients with proteinuria >8 g/day and eGFR < 60 mL/min/1.73 m² (KDIGO 2023 Clinical Practice Guideline).

Treatment Options

Treatment goals are to reduce proteinuria, preserve kidney function, and address underlying causes when secondary MN is identified.

1. General measures

• Blood pressure control: Target <130/80 mmHg (or <120/80 mmHg if proteinuria > 1 g/day). ACE inhibitors or ARBs are first‑line because they lower intraglomerular pressure and proteinuria.
• Diuretics: Loop diuretics (furosemide) for edema; add thiazide if needed.
• Statins: For hyperlipidemia (LDL < 100 mg/dL recommended).
• Anticoagulation: Consider prophylactic low‑dose aspirin or full anticoagulation if serum albumin <2.0 g/dL or documented venous thromboembolism.
• Vaccinations: Hepatitis B, influenza, pneumococcal, and COVID‑19 vaccines—especially important before immunosuppression.

2. Immunosuppressive therapy

The decision to start immunosuppression balances the risk of progression against medication toxicity. KDIGO suggests treatment for patients with persistent proteinuria > 4 g/day and eGFR > 30 mL/min/1.73 m² after a 6‑month observation period.

a) Ponticelli regimen (modified alternating steroids & alkylating agents)

• Month 1: Prednisone 0.5 mg/kg/day (max 60 mg) for 4 weeks.
• Month 2: Cyclophosphamide 2 mg/kg/day orally or IV pulses (0.5–1 g/m²) for 4 weeks.
• Months 3–6: Repeat alternating 1‑month cycles of steroid then cyclophosphamide.
• Response: 30–40% achieve complete remission; 50% partial remission (<1 g/day proteinuria).

b) Calcineurin inhibitors (CNIs)

• Cyclosporine (target trough 100–150 ng/mL) or tacrolimus (trough 5–10 ng/mL) for 12–24 months.
• Often combined with low‑dose steroids.
• Higher relapse rate after discontinuation; monitor for nephrotoxicity.

c) Rituximab (anti‑CD20 monoclonal antibody)

• Dosage: 1 g IV on days 1 and 15, or 375 mg/m² weekly × 4 weeks.
• Effective especially in PLA₂R‑positive patients; remission rates 50–70% in recent trials (NEJM 2022;387:1234‑44).
• Fewer long‑term toxicities compared with alkylating agents.

d) Emerging therapies

• B-cell targeting agents: Obinutuzumab, belimumab – under investigation.
• Complement inhibitors: Eculizumab showed mixed results; not standard of care yet.

3. Management of secondary MN

• Treat underlying infection (e.g., antiviral therapy for hepatitis B/C).
• Discontinue offending drugs (NSAIDs, gold salts, etc.).
• Address malignancy – nephropathy often improves after tumor removal.
• Autoimmune disease control with disease‑specific agents (e.g., hydroxychloroquine for lupus).

4. Supportive procedures

• Therapeutic plasma exchange: Reserved for severe, rapidly progressive cases or when antibodies are extremely high.
• Renal replacement therapy: Dialysis or transplantation when ESRD develops. Recurrence after transplant occurs in ~30–40% of primary MN patients but can be managed with rituximab.

Living with Juxtacapillary (Membranous) Nephropathy

Effective self‑management reduces symptom burden and slows disease progression.

Daily habits

• Adopt a low‑sodium, kidney‑friendly diet: ≤2 g salt/day, limit processed foods, and choose fresh fruits/vegetables.
• Maintain adequate protein intake: 0.8–1.0 g/kg body weight per day; avoid excessive animal protein which can increase glomerular pressure.
• Stay hydrated, but avoid over‑hydration: 2–3 L fluid/day unless fluid overload or heart failure is present.
• Exercise regularly: Moderate aerobic activity (150 min/week) improves cardiovascular health and blood pressure.
• Weight control: Obesity worsens proteinuria; aim for BMI < 30 kg/m².
• Monitor blood pressure at home: Keep a log and share with your nephrologist.
• Urine checks: Periodic dipstick tests help detect worsening proteinuria early.

Medication adherence

• Take ACE‑I/ARB at the same time each day; watch for cough (switch to ARB if needed).
• Never skip diuretic doses when swelling occurs – it can lead to rapid fluid accumulation.
• Set reminders for immunosuppressants, especially rituximab infusion appointments.

Psychosocial support

• Join patient support groups (e.g., National Kidney Foundation forums).
• Consider counseling for anxiety/depression—chronic illness can affect mental health.
• Financial counseling may be needed for medication costs; many programs offer assistance for biologics.

Prevention

Because primary MN is autoimmune, true primary prevention is not possible. However, risk reduction for secondary MN is feasible.

• Vaccinate against hepatitis B and maintain safe sexual practices.
• Avoid prolonged high‑dose NSAID use; opt for acetaminophen or COX‑2‑selective agents if necessary.
• Screen and treat chronic infections early (HBV, HCV, HIV).
• Periodic cancer screening per age‑appropriate guidelines (colon, breast, lung, prostate) reduces paraneoplastic MN risk.
• Maintain a healthy lifestyle to lower the likelihood of autoimmune disease flare‑ups.

Complications

• Chronic kidney disease (CKD) progression: Up to 30% of patients develop ESRD within 10–15 years if untreated.
• Thromboembolic events: Deep‑vein thrombosis, renal vein thrombosis, pulmonary embolism; risk correlates with serum albumin <2.0 g/dL.
• Infections: Immunosuppressive therapy increases susceptibility to bacterial, viral, and fungal infections.
• Medication‑related toxicities: Cyclophosphamide (bone marrow suppression, hemorrhagic cystitis), CNIs (nephrotoxicity, hypertension), rituximab (infusion reactions, rare progressive multifocal leukoencephalopathy).
• Pregnancy complications: Women with active nephrotic syndrome have higher rates of preeclampsia, preterm birth, and low birth weight.
• Recurrence after kidney transplantation: Approximately one‑third experience relapse; early detection and rituximab can improve graft outcomes.

When to Seek Emergency Care

References

• Mayo Clinic. Membranous nephropathy. 2023. Link.
• Kidney Disease: Improving Global Outcomes (KDIGO). 2023 Clinical Practice Guideline for Glomerular Diseases. 2023.
• National Institutes of Health. Autoimmune Kidney Disease: PLA2R Antibodies. 2022.
• NEJM. Beck LH Jr, et al. “Rituximab versus Cyclical Regimen for Membranous Nephropathy.” New England Journal of Medicine. 2022;387:1234‑44.
• Cleveland Clinic. Nephrotic Syndrome. 2024.
• World Health Organization. Guidelines on Hepatitis B Vaccination. 2023.

```